Forskolin inhibits platelet deposition in small diameter polytetrafluoroethylene grafts.
Synthetic vascular grafts have a thrombogenic surface which probably is an important factor in graft failure. Systemic pharmacologic intervention has been used but is associated with side effects. In this communication we describe the results of a new therapeutic principle of applying forskolin, a powerful cyclic adenosine monophosphate stimulator (cAMP), to the inner surface of a synthetic graft material, polytetrafluoroethylene. Evaluation was done with Indium-111-oxine labelled platelets and histopathology. It was found that forskolin significantly lowers the platelet deposition onto the treated graft surface compared to controls.
Christenson
J T
JT
Department of Surgery, Faculty of Medicine, Kuwait University.
Thulesius
O
O
Al-Huneidi
W
W
D000818:Animals; D001783:Blood Flow Velocity; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D001807:Blood Vessel Prosthesis; D005576:Colforsin / Q000008:administration & dosage / Q000494:pharmacology*; D007205:Indium Radioisotopes; D008297:Male; D009942:Organometallic Compounds; D015125:Oxyquinoline / Q000031:analogs & derivatives; D011138:Polytetrafluoroethylene; D012756:Sheep; D014654:Vascular Patency
D007205:Indium Radioisotopes; D009942:Organometallic Compounds; C032950:indium oxine; D005576:Colforsin; D015125:Oxyquinoline; D011138:Polytetrafluoroethylene